BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37227081)

  • 41. Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.
    Chen GL; Li D; Cao S; Jiang S; Zhang Q; Jin J; Xia Z; Liu Y; Liu X; Zhu Y; Chen Y; Gu L; Hong X; Cao J; Tao R; Lv F
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022066. PubMed ID: 36119461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma.
    Pan BH; Kong YL; Wang L; Zhu HY; Li XT; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Leuk Lymphoma; 2021 Feb; 62(2):291-299. PubMed ID: 33063579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
    Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
    Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
    J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiomics signature from [
    Jiang C; Huang X; Li A; Teng Y; Ding C; Chen J; Xu J; Zhou Z
    Eur Radiol; 2022 Aug; 32(8):5730-5741. PubMed ID: 35298676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma.
    Shimono J; Takahashi S; Takemura R; Kakinoki Y
    Int J Lab Hematol; 2019 Dec; 41(6):754-761. PubMed ID: 31529774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Artificial intelligence-based prognostic model accurately predicts the survival of patients with diffuse large B-cell lymphomas: analysis of a large cohort in China.
    Peng H; Su M; Guo X; Shi L; Lei T; Yu H; Xu J; Pan X; Chen X
    BMC Cancer; 2024 May; 24(1):621. PubMed ID: 38773392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 52. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
    Shen Y; Wang L; Ou J; Wang B; Cen X
    Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
    [No Abstract]   [Full Text] [Related]  

  • 53. The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma.
    Wang WT; Liang JH; Wang L; Zhu HY; Xia Y; Fan L; Li JY; Xu W
    Ann Hematol; 2020 Oct; 99(10):2377-2384. PubMed ID: 32728938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
    Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
    BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
    Huang H; Datye A; Fan M; Knapp A; Nielsen T; Bottos A; Paulson JN; Trask PC; Efficace F
    Cancer Med; 2022 Sep; 11(17):3312-3322. PubMed ID: 35322932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma.
    Liu T; Ye F; Li Y; Liu A
    Ann Palliat Med; 2021 Sep; 10(9):9650-9659. PubMed ID: 34628890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
    Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
    Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
    Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.